Results 201 to 210 of about 102,809 (247)

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

Extracellular vesicles released from melanoma cells constitutively expressing MHC class II promote immune evasion and cancer progression

The FEBS Journal, EarlyView.
Here, we report the role of extracellular vesicles (EVs) released from melanoma cells constitutively expressing MHC class II in the regulation of immune cell functions and melanoma metastasis. In particular, we observed an increased localization of HLA‐DRα, CAM receptors, PD‐L1, and STAT3 signaling proteins in the EVs.
Francesca Costantini, Caterina Di Sano, Samuele Raccosta, Mauro Manno, Giovanna Barbieri   +4 more
wiley   +1 more source

Beyond the chaos: How architecture structures tumour biology

The FEBS Journal, EarlyView.
Tissue architecture shapes tumour initiation and progression through multiple interconnected layers continuously remodelled over time. This review outlines how physical forces, biochemical cues, cellular niches and systemic influences contribute to tumour evolution.
Lea Dörner, Catrin Lutz, Stefan Prekovic, Hendrik A. Messal   +3 more
wiley   +1 more source

Degradomics for large‐scale mechanistic insights on proteases and proteolysis in human health

The FEBS Journal, EarlyView.
Proteolysis has an important role in human disease but remains relatively unexplored. Degradomics, the uncovering of proteolysis in tissues, cells, and proteins, uses mass spectrometry‐based terminomics to identify protein termini occurring therein (forward degradomics) and to define the actions of proteases (reverse degradomics).
Daniel R. Martin, Sumit Bhutada, Suneel S. Apte   +2 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Porcine major histocompatibility complex.

Revue scientifique et technique (International Office of Epizootics), 1998
The major histocompatibility complex in swine (swine leucocyte antigen: SLA) is located on chromosome 7 with the class I and class III regions separated by the centromere from the class II region. The overall molecular organisation of the class I and III regions is well known, but further research is needed to establish that of the class II region ...
Vaiman, M., Chardon, Patrick, Rothschild, M.F.   +2 more
openaire   +2 more sources

Major histocompatibility complex

Nature, 1977
Histocompatibility. By George D. Snell, Jean Dausset and Stanley Nathenson. Pp. xiv + 401. (Academic: New York, San Francisco and London, 1976.) $29.50; £18.
openaire   +1 more source

COMPLEXITY IN THE MAJOR HISTOCOMPATIBILITY COMPLEX

International Journal of Immunogenetics, 1992
SUMMARYThe human major histocompatibility complex (MHC) is one of the most intensively studied regions of the human genome, containing over 70 known genes and spanning about 4 million base pairs (4Mbp) of DNA on chromosome 6p21.3 (Klein, 1986). It can be divided up into three regions: the class I region (telomeric), the class II region (centromeric ...
J, Trowsdale, R D, Campbell
openaire   +2 more sources

The major histocompatibility complex origin

Immunological Reviews, 2004
Summary:  The present review focuses on the history of genes involved in the major histocompatibility complex (MHC), with a special emphasis on class I function in peptide presentation. The MHC class II story is covered in less detail, as it does not have a major impact on the general understanding of the MHC evolution. We first redefine the MHC as the
Danchin, Etienne, Vitiello, Vérane, Vienne, Alexandre, Richard, Olivier, Gouret, Philippe, Mcdermott, Michael F, Pontarotti, Pierre   +6 more
openaire   +3 more sources

New major histocompatibility complex genes

Human Immunology, 1993
The MHC is a region of some 4 megabases that has been studied intensively owing to the large number of diseases that are associated with susceptibility genes within this region of the genome. The total number of genes located within the MHC is now approximately 100, but more can be predicted.
B, Marshall, C, Leelayuwat, M A, Degli-Esposti, M, Pinelli, L J, Abraham, R L, Dawkins   +5 more
openaire   +2 more sources